Manuel Hidalgo

Manuel Hidalgo a leading physician-scientist specializing in pancreatic cancer and drug development, is the Chief of the Division of Hematology and Medical Oncology and E. Hugh Luckey Distinguished Professor of Medicine at Weill Cornell Medicine/New York-Presbyterian Hospital. Dr Hidalgo is also Associate Director for Clinical Services at the Sandra and Edward Meyer Cancer Center. His research has included the development of several anti-cancer drugs including erlotinib, nab-paclitaxel and temsirolimus. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and his Ph.D. from the University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital “12 de Octubre” in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo become the Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, Johns Hopkins University, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. During his time at Beth Israel, Dr. Hidalgo served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School.